Clinical Trial

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-03-17; most recent amendment 2026-05-15.
Status change: Recruiting → Active, Not Recruiting 2023-06-30
Status change: Not Yet Recruiting → Recruiting 2022-05-31
Trial Details
NCT Number NCT05297890
Lead Sponsor CStone Pharmaceuticals
Collaborators: Pfizer
Conditions Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Enrollment 70 participants
Start Date 2022-05-27
Primary Completion 2023-12-26 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-19